Literature DB >> 31154554

Is serum uric acid a predictor of long-term renal outcome in lupus nephritis?

Michelle Remião Ugolini-Lopes1, Samara S Gavinier2, Elaine Leon2, Vilma Trindade Viana2, Eduardo Ferreira Borba2, Eloisa Bonfá2.   

Abstract

BACKGROUND/
OBJECTIVE: Recent studies observed an association between increased serum uric acid (SUA) levels and renal damage in lupus. However, the predictive value of UA for the development of long-term renal dysfunction in lupus nephritis (LN) is still unknown. The aim of this study was to evaluate if SUA may be a predictor of long-term renal outcome in LN.
METHODS: Eighty biopsy-proven LN patients > 7 years of follow-up were selected. SUA levels were measured in sera stored at - 70 °C. All patients had serum stored from LN baseline, and 32 also had stored serum from 6 and 12 months after LN. Renal outcome was addressed after 7 years of follow-up to determine if SUA could be a predictor of long-term renal outcome. A good long-term renal outcome in 7 years was defined as a creatinine clearance (CrCl) ≥ 90.0 mL/min/1.73 m2, and poor if CrCl < 90 mL/min/1.73 m2. Patients were divided in two groups according to the renal outcome to assess whether SUA levels at different time points of follow-up could differentiate such groups. An ROC curve was plotted to assess accuracy.
RESULTS: SUA levels at baseline and 6 months were not able to differentiate good from poor long-term renal outcomes in LN (respectively p = 0.37, p = 0.28), but at 12 months (p = 0.02), they could clearly differentiate the two groups. ROC curve (12 months) accuracy was 0.76. SUA cutoff was 6.05 mg/dL (sensitivity = 0.67, specificity = 0.89, positive predictive value = 0.85, negative predictive value = 0.73).
CONCLUSION: SUA levels < 6.05 mg/dL at 12 months of follow-up is a predictor of good long-term renal outcome in lupus nephritis. KEY POINTS: • Previous studies reported an association between increased serum uric acid level and short-term renal damage in lupus patients. • The predictive value of serum uric acid for the development of long-term renal dysfunction in lupus nephritis was never assessed. • At 12 months of follow-up serum uric acid clearly differentiated good from poor long-term renal outcome in lupus nephritis. • SUA level < 6.05 mg/dL at 12 months of follow-up was a predictor of good long-term renal outcome in lupus nephritis.

Entities:  

Keywords:  Chronic kidney disease; Lupus nephritis; Outcome; Predictor; Serum uric acid

Mesh:

Substances:

Year:  2019        PMID: 31154554     DOI: 10.1007/s10067-019-04620-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

Review 1.  [Treat-to-target in rheumatology].

Authors:  Maria Majdan
Journal:  Wiad Lek       Date:  2015

2.  Renal function assessment in patients with systemic lupus erythematosus.

Authors:  Marco Ulises Martínez-Martínez; Jaime Antonio Borjas-García; Martín Magaña-Aquino; Enrique Cuevas-Orta; Lilia Llamazares-Azuara; Carlos Abud-Mendoza
Journal:  Rheumatol Int       Date:  2011-05-21       Impact factor: 2.631

Review 3.  Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease.

Authors:  John Kanellis; Duk-Hee Kang
Journal:  Semin Nephrol       Date:  2005-01       Impact factor: 5.299

Review 4.  Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease.

Authors:  Duk-Hee Kang; Takahiko Nakagawa
Journal:  Semin Nephrol       Date:  2005-01       Impact factor: 5.299

5.  Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients.

Authors:  C Reátegui-Sokolova; Manuel F Ugarte-Gil; Rocío V Gamboa-Cárdenas; Francisco Zevallos; Jorge M Cucho-Venegas; José L Alfaro-Lozano; Mariela Medina; Zoila Rodriguez-Bellido; Cesar A Pastor-Asurza; Graciela S Alarcón; Risto A Perich-Campos
Journal:  Clin Rheumatol       Date:  2017-01-18       Impact factor: 2.980

6.  Serum uric acid levels are associated with lupus nephritis in patients with normal renal function.

Authors:  Ana Luisa Calich; Eduardo Ferreira Borba; Michelle Remião Ugolini-Lopes; Luiza Fuoco da Rocha; Eloisa Bonfá; Ricardo Fuller
Journal:  Clin Rheumatol       Date:  2018-01-20       Impact factor: 2.980

7.  Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.

Authors:  D T Boumpas; H A Austin; E M Vaughn; J H Klippel; A D Steinberg; C H Yarboro; J E Balow
Journal:  Lancet       Date:  1992-09-26       Impact factor: 79.321

8.  Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization.

Authors:  G B Appel; D J Cohen; C L Pirani; J I Meltzer; D Estes
Journal:  Am J Med       Date:  1987-11       Impact factor: 4.965

Review 9.  Uric acid and cardiovascular risk.

Authors:  Daniel I Feig; Duk-Hee Kang; Richard J Johnson
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?

Authors:  Michelle R Ugolini-Lopes; Luciana Parente C Seguro; Maitê Xavier F Castro; Danielle Daffre; Alex C Lopes; Eduardo F Borba; Eloisa Bonfá
Journal:  Lupus Sci Med       Date:  2017-06-12
View more
  2 in total

1.  Clinicopathological Patterns and Outcomes in Patients with Lupus Nephritis and Hyperuricemia.

Authors:  Qiong Wen; Xueqing Tang; Qian Zhou; Wei Chen; Xueqing Yu
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

2.  Serum uric acid is associated with damage in patients with systemic lupus erythematosus.

Authors:  Claudia Elera-Fitzcarrald; Cristina Reátegui-Sokolova; Rocio Violeta Gamboa-Cardenas; Mariela Medina; Francisco Zevallos; Victor Román Pimentel-Quiroz; Jorge Mariano Cucho-Venegas; José Alfaro-Lozano; Zoila Rodriguez-Bellido; Cesar Augusto Pastor-Asurza; Risto Alfredo Perich-Campos; Graciela S Alarcón; Manuel Francisco Ugarte-Gil
Journal:  Lupus Sci Med       Date:  2020-02-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.